钠葡萄糖协同转运蛋白2抑制剂在心力衰竭中的作用:潜在机制、临床应用及临床试验总结
本文综述SGLT2抑制剂的药效学及其在心力衰竭中应用的理由。EMPA-REG OUTCOME和CANVAS试验显示SGLT2抑制剂可降低2型糖尿病合并心血管疾病患者的心衰住院风险,机制涉及利钠、渗透性利尿、降低前负荷及改善血流动力学,且可能独立于降糖作用。
要点
- SGLT2抑制剂在T2D合并心血管疾病患者中降低心衰住院风险。
- 机制包括利钠、渗透性利尿、降低前负荷和血压,可能独立于降糖。
- 正在进行的临床试验探索SGLT2抑制剂在伴或不伴T2D的心衰患者中的应用。
核心结论
- SGLT2抑制剂在2型糖尿病合并心血管疾病患者中显示降低心衰住院风险,且可能独立于降糖作用,支持其在心衰患者中的进一步研究。
研究设计与样本
- 综述总结了SGLT2抑制剂的关键药效学效应、支持其在心衰患者中应用的临床证据,并概述了正在进行的心血管结局试验。
主要发现
- EMPA-REG OUTCOME试验显示恩格列净在2型糖尿病合并心血管疾病患者中显著降低死亡率和心衰住院风险。
- CANVAS试验报告卡格列净降低3点主要不良心血管事件和心衰住院风险。
- SGLT2抑制促进利钠和渗透性利尿,导致血浆容量收缩、前负荷降低,并降低血压、动脉硬度和后负荷,从而改善心内膜下血流。
- SGLT2抑制与肾功能保护相关。
临床怎么用
- 对于2型糖尿病合并心血管疾病患者,可考虑使用SGLT2抑制剂以降低心衰住院风险。
- SGLT2抑制剂在无2型糖尿病的心衰或心衰风险患者(如冠心病或高血压患者)中的潜在应用正在研究中。
局限性
- SGLT2抑制剂的心脏保护机制尚未完全明确。
- 目前证据主要来自2型糖尿病合并心血管疾病患者,在无2型糖尿病心衰患者中的数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite current established therapy, heart failure (HF) remains a leading cause of hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to improve the prognosis of patients with HF. The EMPA-REG OUTCOME trial ([Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) demonstrated significant reductions in mortality and HF hospitalization risk in patients with type 2 diabetes mellitus (T2D) and cardiovascular disease with the antihyperglycemic agent, empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor. The CANVAS trial (Canagliflozin Cardiovascular Assessment Study) subsequently reported a reduction in 3-point major adverse cardiovascular events and HF hospitalization risk. Although SGLT2 inhibition may have potential application beyond T2D, including HF, the mechanisms responsible for the cardioprotective effects of SGLT2 inhibitors remain incompletely understood. SGLT2 inhibition promotes natriuresis and osmotic diuresis, leading to plasma volume contraction and reduced preload, and decreases in blood pressure, arterial stiffness, and afterload as well, thereby improving subendocardial blood flow in patients with HF. SGLT2 inhibition is also associated with preservation of renal function. Based on data from mechanistic studies and clinical trials, large clinical trials with SGLT2 inhibitors are now investigating the potential use of SGLT2 inhibition in patients who have HF with and without T2D. Accordingly, in this review, we summarize the key pharmacodynamic effects of SGLT2 inhibitors and the clinical evidence that support the rationale for the use of SGLT2 inhibitors in patients with HF who have T2D. Because these favorable effects presumably occur independent of blood glucose lowering, we also explore the potential use of SGLT2 inhibition in patients without T2D with HF or at risk of HF, such as in patients with coronary artery disease or hypertension. Finally, we provide a detailed overview and summary of ongoing cardiovascular outcome trials with SGLT2 inhibitors.
引用
- Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017. PMID: 29061576. doi:10.1161/CIRCULATIONAHA.117.030012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。